← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Via Therapeutics, Llc
Austin, TX
$8,293,150
Total funding
11
Grants
Funding over time
peak $3.3M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,293,150 · 11
By mechanism
N01$3,599,145 · 1
N44$1,468,122 · 1
R41$1,192,621 · 4
R44$1,000,000 · 1
R43$733,267 · 3
N43$299,995 · 1
Investigators at Via Therapeutics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Inhaled Delivery of Clofazimine - A High Efficiency, Flow Independent, Targeted, Low Cost DPI$2,999,221
N44 · FY2020 · AI
Phase II: Development of Low-Cost, Shelf-Stable Treatment for Tuberculosis$1,468,122
N44 · FY2023 · AI
Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza$1,000,000
R44 · FY2025 · AI
Inhaled Delivery of Clofazimine - A High Efficiency, Flow Independent, Targeted, Low Cost DPI$599,924
N01 · FY2018 · AI
Combined Amikacin and Azithromycin in an Inhaled Formulation for the Treatment of NTM$314,363
R41 · FY2025 · AI
Microneedle-based mRNA Flu Vaccine for Transcutaneous Immunization$314,363
R41 · FY2025 · AI
Inhalable dry powders of mycobacteriophages for tuberculosis therapy$300,000
R41 · FY2024 · AI
Pediatric Formulations of Select Second Line Drugs for Treating Tuberculosis$299,995
N43 · FY2021 · AI
Enabling the repurposing of niclosamide for castrate-resistant prostate cancer using a novel formulation technology platform$263,895
R41 · FY2020 · CA
Development of synergistic clofazimine-amikacin inhalable powders for the treatment of pulmonary Mycobacterium abscessus infections$256,350
R43 · FY2021 · AI
Discovery of epidermal/dermal targeting formulations for cutaneous squamous cell carcinoma$251,917
R43 · FY2021 · CA
Preclinical evaluation of co-delivery of TNF-alpha siRNA and a glucocorticoid for rheumatoid arthritis$225,000
R43 · FY2018 · AR